Abstract
Inotuzumab Ozogamicin (InO) for Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the Global Phase 3 INO-VATE Trial: Efficacy By MLL Status
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have